The medtech industry will lose a champion in Congress when Senate Finance Panel Chair Orrin Hatch, R-Utah, retires at the end of the 2018 congressional session. Author of the Americans with Disabilities Act and the Children's Health Insurance Program law, Hatch has been a perennial supporter of device-tax repeal, introduced market-based pricing for lab test reimbursements, and sponsored deep cuts in taxes for corporations in tax reform legislation signed into law just last month. Might former Massachusetts governor and failed 2008 US presidential candidate Mitt Romney run for the soon-to-be vacated seat?
Senate Finance Committee Chairman Orrin Hatch, R-Utah, has announced plans to retire at the end of the current legislative session this year, most likely in December. He will leave big shoes to fill on the panel that handles Medicare and Medicaid reimbursements, tax reforms and trade issues.
Hatch is 83, and ready for retirement, he said when announcing his retirement on Jan. 2. "I've always been a...
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.
J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.
